Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | COMT | P21964 | 15/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14827207 | 0.83 | COMT (0.71) | COMT | |
| SCHEMBL2440018 | 0.83 | COMT (0.71) | COMT | |
| SCHEMBL14816050 | 0.81 | COMT (0.68) | COMT | |
| SCHEMBL14816437 | 0.81 | COMT (0.73) | COMT | |
| SCHEMBL14815808 | 0.80 | COMT (0.66) | COMT | |
| SCHEMBL6901220 | 0.79 | COMT (1.00) | COMT | |
| SCHEMBL6901213 | 0.78 | COMT (0.64) | COMT | |
| SCHEMBL6900337 | 0.77 | COMT (0.62) | COMT | |
| SCHEMBL14827201 | 0.76 | COMT (0.77) | COMT | |
| SCHEMBL6900205 | 0.75 | COMT (0.78) | COMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9399651-B2 | Inhibitors of catechol O-methyl transferase and their use in the treatment of psychotic disorders | Merck, Sharp & Dohme Corp. (US) | 2016-07-26 | — | — | US | disclosed |
| US-20150299227-A1 | INHIBITORS OF CATECHOL O-METHYL TRANSFERASE AND THEIR USE IN THE TREATMENT OF PSYCHOTIC DISORDERS | MERCK SHARP & DOHME CORP. (US) | 2015-10-22 | — | — | US | disclosed |
| US-9024032-B2 | Inhibitors of catechol O-methyl transferase and their use in the treatment of psychotic disorders | MERCK SHARP & DOHME CORP. (US) | 2015-05-05 | — | — | US | disclosed |
| US-20130084346-A1 | INHIBITORS OF CATECHOL O-METHYL TRANSFERASE AND THEIR USE IN THE TREATMENT OF PSYCHOTIC DISORDERS | MERCK SHARP & DOHME LLC | 2013-04-04 | — | — | US | disclosed |
| US-8222279-B2 | Small molecule insulin mimetics absent quinones | DUKE UNIVERSITY (US) | 2012-07-17 | — | — | US | disclosed |
| US-20110028519-A1 | SMALL MOLECULE INSULIN MIMETICS ABSENT QUINONES | PIRRUNG MICHAEL C | 2011-02-03 | — | — | US | disclosed |
| US-7834050-B2 | Use of indole compounds such as 3-Hydroxy-6-hydroxymethyl-1-methyl-2-[7-(3-methyl-but-2-enyl)-1H-indol-3-yl]-pyridin-4-one | DUKE UNIVERSITY (US) | 2010-11-16 | — | — | US | disclosed |
| US-20070232663-A1 | SMALL MOLECULE INSULIN MIMETICS ABSENT QUINONES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2007-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028519-A1 | SMALL MOLECULE INSULIN MIMETICS ABSENT QUINONES | IAPP, GPR119, IRS1 | COMT 1858/4885 |
| US-20150299227-A1 | INHIBITORS OF CATECHOL O-METHYL TRANSFERASE AND THEIR USE IN THE TREATMENT OF PSYCHOTIC DISORDERS | COMT, PNMT, TPMT | COMT 1/4885 |
| US-20070232663-A1 | SMALL MOLECULE INSULIN MIMETICS ABSENT QUINONES | IAPP, GPR119, IRS1 | COMT 1858/4885 |
| US-20130084346-A1 | INHIBITORS OF CATECHOL O-METHYL TRANSFERASE AND THEIR USE IN THE TREATMENT OF PSYCHOTIC DISORDERS | COMT, PNMT, TPMT | COMT 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.